Keep current on the latest news from Allegro Ophthalmics

Sign up today to be notified about the initiation of clinical trials, study results and breaking company news.

Your info will never be shared with a third-party

No Thanks

Doctor-patient interaction

Loss of vision is a serious risk for millions of people suffering from diabetic macular edema caused by diabetes.

Doctors and patients need additional treatment options

Luminate® can provide therapeutic benefit to both anti-VEGF-responsive and DME patients who don’t respond adequately to the current standard of care1

  • Only 50% of subjects with DME show adequate response to anti-VEGF therapy – the current standard of care2


Luminate® brings an exciting opportunity to the market that includes a way to provide quick, safe, and cost-effective treatment for DME patients in need.1

With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to establishing integrin peptide therapy as the next generation pharmaceutical category for the treatment of vitreoretinal diseases, including DME and age-related macular degeneration.

More About DME

Diabetic macular edema (DME) is a potentially blinding condition associated with the growing epidemic of diabetes. Individuals with diabetes experience fluid and blood accumulation within the retina, which causes DME – and potentially loss of vision and blindness.3

DME is an increasingly common burden to individuals, specifically those in their working years. Statistics show that approximately 1 in 25 persons aged 40 and greater with diabetes has DME in at least 1 eye.4 With diabetes increasing in the U.S., DME is expected to increase as well.5

Allegro is committed to offering patients self-sufficient, functional vision.

We invite you to learn more about Allegro Ophthalmics and Luminate® as we plan for phase 3 of our clinical trials for the treatment of DME.


References: 1. Data on file. 2. Singer MA, Kermany DS, Waters J, et al. F1000Res. 2016;5. 3. Mayo Clinic. Diabetic macular edema. Accessed September 19, 2017. 4. Varma R, Bressler NM, Doan QV, et al. JAMA Ophthalmol. 2014;132(11):1334-1340. 5. Centers for Disease Control and Prevention (CDC). Long-term trends in diabetes. April 2017.